The massive shelf and ATM signal severe financial distress. Short-sellers should watch for actual ATM sales (daily volume reveals). Long holders face extreme dilution risk. Expect continued downward pressure as the market prices in future equity issuance. Monitor insider selling and any new drug catalysts that could offset dilution.
Price Chart
Executive Summary
Karyopharm filed a $400M universal shelf registration (including a $100M ATM) representing ~202% of its $198M market cap. The company's auditor flagged substantial doubt about its ability to continue as a going concern, and the massive potential dilution signals severe capital needs. This is a highly dilutive and desperate capital raise for a struggling commercial-stage biotech.
Key Facts
- Filed S-3 shelf for up to $400M in securities (debt, common, preferred, warrants, units)
- Includes a $100M at-the-market (ATM) offering via Jefferies, up to 3% commission
- Stock at $8.40, market cap ~$198M — shelf is 202% of market cap; ATM is ~50%
- Auditors' report includes going concern uncertainty (Ernst & Young, FY2025 10-K)
- Assuming $8.40/share, full ATM draw would issue ~11.9M shares (53% dilution vs 22.6M shares outstanding)
- Net tangible book value per share was -$96.09; after full ATM draw would be -$55.04 per share
- Proceeds for general corporate purposes — no specific use identified
Financial Impact
Up to $400M in potential dilution (~202% of current market cap); $100M ATM alone represents 53% dilution at $8.40/share
Risk Factors
- Dilution of up to 200%+ if full shelf is utilized
- Going concern status — risk of bankruptcy if capital not raised
- ATM sales will pressure stock price mechanically
- No clear revenue growth to absorb dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-204130 |
| Document: d69189dex41.htm | 0001193125-26-204130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access